GlassScriptPhysician profile
Douglas Clark
NPI 1326038035
$13,782.21
in general payments reported to CMS, 2019-2025
21 companies · $2,634 in 2025
The $2,634 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,261 · 2022: $1,521 · 2023: $2,269 · 2024: $6,097 · 2025: $2,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,295 · Consulting Fee: $3,443 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,295.04 |
| Consulting Fee | $3,442.80 |
| Education | $262.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $4,592.12 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $1,522.08 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $1,406.28 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,326.72 | 2021-2025 | Ilumya, Winlevi |
| Abbvie INC. | $1,172.89 | 2021-2025 | |
| Leo Pharma INC. | $814.01 | 2021-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $703.65 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $528.05 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $426.54 | 2021-2025 | |
| Pfizer INC. | $336.12 | 2021-2025 | |
| Incyte Corporation | $248.81 | 2022-2025 | Opzelura |
| Amgen INC. | $206.55 | 2022-2023 | Otezla |
| Regeneron Healthcare Solutions, INC. | $127.27 | 2021-2025 | Dupixent |
| Galderma Laboratories, L.P. | $120.83 | 2024-2025 | Nemluvio, Aklief |
| Eli Lilly and Company | $99.00 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $46.55 | 2023-2024 | Vtama |
| Kyowa Kirin, INC. | $25.76 | 2021 | |
| Organon LLC | $22.56 | 2025 | Vtama |
| Organogenesis INC. | $21.30 | 2024 | |
| Genentech USA, INC. | $20.15 | 2024 | Erivedge |
| Arcutis Biotherapeutics, INC. | $14.97 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.